The inspection, a follow-up audit under Good Manufacturing Practices (GMP), was conducted between June 9 and June 18, 2025, at the company’s facility located in SEZ 1 near Matoda, Ahmedabad.
Also Read: 8 debt-free penny stocks that surged 110-300% in the last 1 year. Do you own any?
In a regulatory filing, Zydus Lifesciences said the observations were minor and that it is working closely with the US FDA to address and respond to them promptly.
This comes shortly after the company received the Establishment Inspection Report (EIR) from the US FDA for its active pharmaceutical ingredient (API) manufacturing facility in Ankleshwar, Gujarat. The inspection at the Ankleshwar site was carried out from March 10 to March 14, 2025, and was classified as ‘No Action Indicated’ (NAI), meaning the FDA found no objectionable conditions. With this classification, the inspection is now considered closed.
Also Read: Street favourites! Analysts see these 10 smallcap stocks rallying 20-80%
Zydus Lifesciences share price target
According to Trendlyne, the average target price for Zydus Lifesciences is Rs 984, indicating a potential upside of around 3% from current levels. Of the 31 analysts tracking the stock, the consensus rating remains ‘Hold’.On the technical front, the Relative Strength Index (RSI) is currently at 60.3. An RSI below 30 typically indicates an oversold stock, while a reading above 70 suggests it is overbought. The stock is trading above its 20-day, 50-day, and 100-day simple moving averages but remains below its 200-day SMA.Zydus Lifesciences shares have declined around 11% over the past 12 months. However, the stock has delivered a strong return of 74% over the past two years. The company’s current market capitalisation stands at approximately Rs 96,377 crore.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
By
